Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection

Current Opinion in Infectious Diseases

Volumn 28, Issue 1, 2015, Pages 97-105

  O'Brien, Valerie P ^a   Hannan, Thomas J ^b   Schaeffer, Anthony J ^c   Hultgren, Scott J ^a,b  

^a Center for Womens Infectious Disease Research   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cystitis; mucosal immunology; urinary tract infection; uropathogenic Escherichia coli

Indexed keywords

BACTERIAL COLONIZATION; CYSTITIS; ESCHERICHIA COLI INFECTION; HUMAN; IMMUNOPATHOLOGY; INFECTION SENSITIVITY; INNATE IMMUNITY; NONHUMAN; RECURRENT INFECTION; REVIEW; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; ANIMAL; BLADDER; DISEASE MODEL; DISEASE PREDISPOSITION; ESCHERICHIA COLI; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; MOUSE; MUCOSA; PATHOGENICITY; PATHOLOGY; TIME;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MICE; MUCOUS MEMBRANE; TIME FACTORS; URINARY BLADDER; URINARY TRACT INFECTIONS;

EID: 84920923272     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000130     Document Type: Review

References (101)

1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 2003; 49:53-70.
2. Foxman B, Barlow R, D'Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000; 10:509-515.
3. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113 (Suppl 1A):5S-13S.
4. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014; 28:1-13.
5. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for. Vital Health Stat 13 2007; 2011:1-38.
6. Ikaheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 1996; 22:91-99.
7. Hopkins WJ, Elkahwaji J, Beierle LM, et al. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol 2007; 177:1349-1353.
8. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7:653-660.
9. Al-Badr A, Al-Shaikh G. Recurrent urinary tract infections management in women: a review. Sultan Qaboos Univ Med J 2013; 13:359-367.
10. Williams G, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2011; CD001534.
11. Taneja N, Rao P, Arora J, Dogra A. Occurrence of ESBL & Amp-C betalactamases & susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res 2008; 127:85-88.
12. Marrs CF, Zhang L, Foxman B. Escherichia coli mediated urinary tract infections: are there distinct uropathogenic E. coli (UPEC) pathotypes? FEMS Microbiol Lett 2005; 252:183-190.
13. Ragnarsdottir B, Samuelsson M, Gustafsson MC, et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 2007; 196:475-484.
14. Ragnarsdottir B, Lutay N, Gronberg-Hernandez J, et al. Genetics of innate immunity and UTI susceptibility. Nat Rev Urol 2011; 8:449-468.
15. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997; 11:551-581.
16. Scholes D, Hooton TM, Roberts PL, et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 2005; 142:20-27.
17. Melekos MD, Naber KG. Complicated urinary tract infections. Int J Antimicrob Agents 2000; 15:247-256.
18. Anderson GG, Palermo JJ, Schilling JD, et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003; 301:105-107.
19. Justice SS, Hung C, Theriot JA, et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci U S A 2004; 101:1333-1338.
20. Rosen DA, Pinkner JS, Jones JM, et al. Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression. Infect Immun 2008; 76:3337-3345.
21. Rosen DA, Hooton TM, Stamm WE, et al. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007; 4:e329.
22. Robino L, Scavone P, Araujo L, et al. Detection of intracellular bacterial communities in a child with Escherichia coli recurrent urinary tract infections. Pathogens Dis 2013; 68:78-81.
23. Robino L, Scavone P, Araujo L, et al. Intracellular bacteria in the pathogenesis of Escherichia coli urinary tract infection in children. Clin Infect Dis 2014; 59:e158-e164.
24. Hurst RE, Zebrowski R. Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol 1994; 152 (5 Pt 1):1641-1645.
25. Hu P, Meyers S, Liang FX, et al. Role of membrane proteins in permeability barrier function: uroplakin ablation elevates urothelial permeability. Am J Physiol Renal Physiol 2002; 283:F1200-F1207.
26. Bishop BL, Duncan MJ, Song J, et al. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat Med 2007; 13:625-630.
27. Wu XR, Kong XP, Pellicer A, et al. Uroplakins in urothelial biology, function, and disease. Kidney Int 2009; 75:1153-1165.
28. Springall T, Sheerin NS, Abe K, et al. Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nat Med 2001; 7:801-806.
29. Bates JM, Raffi HM, Prasadan K, et al. Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 2004; 65:791-797.
30. Chromek M, Slamova Z, Bergman P, et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 2006; 12:636-641.
31. de Man P, van Kooten C, Aarden L, et al. Interleukin-6 induced at mucosal surfaces by gram-negative bacterial infection. Infect Immun 1989; 57:3383-3388.
32. Hedges S, Anderson P, Lidin-Janson G, et al. Interleukin-6 response to deliberate colonization of the human urinary tract with gram-negative bacteria. Infect Immun 1991; 59:421-427.
33. Hirose T, Kumamoto Y, Matsukawa M, et al. Study on local immune response in Escherichia coli-induced experimental urinary tract infection in mice - infiltration of Ia-positive cells, macrophages, neutrophils, T cells and B cells. Kansenshogaku Zasshi 1992; 66:964-973.
34. Hopkins WJ, James LJ, Balish E, Uehling DT. Congenital immunodeficiencies in mice increase susceptibility to urinary tract infection. J Urol 1993; 149:922-925.
35. Ko YC, Mukaida N, Ishiyama S, et al. Elevated interleukin-8 levels in the urine of patients with urinary tract infections. Infect Immun 1993; 61:1307-1314.
36. Haraoka M, Hang L, Frendeus B, et al. Neutrophil recruitment and resistance to urinary tract infection. J Infect Dis 1999; 180:1220-1229.
37. Jones-Carson J, Balish E, Uehling DT. Susceptibility of immunodeficient gene-knockout mice to urinary tract infection. J Urol 1999; 161:338-341.
38. Godaly G, Hang L, Frendeus B, Svanborg C. Transepithelial neutrophil migration is CXCR1 dependent in vitro and is defective in IL-8 receptor knockout mice. J Immunol 2000; 165:5287-5294.
39. Mysorekar IU, Mulvey MA, Hultgren SJ, Gordon JI. Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli. J Biol Chem 2002; 277:7412-7419.
40. Schilling JD, Martin SM, Hung CS, et al. Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli. Proc Natl Acad Sci U S A 2003; 100:4203-4208.
41. Malaviya R, Ikeda T, Abraham SN, Malaviya R. Contribution of mast cells to bacterial clearance and their proliferation during experimental cystitis induced by type 1 fimbriated E. coli. Immunol Lett 2004; 91:103-111.
42. Engel D, Dobrindt U, Tittel A, et al. Tumor necrosis factor alpha- and inducible nitric oxide synthase-producing dendritic cells are rapidly recruited to the bladder in urinary tract infection but are dispensable for bacterial clearance. Infect Immun 2006; 74:6100-6107.
43. Andersen-Nissen E, Hawn TR, Smith KD, et al. Cutting edge: Tlr5-/- mice are more susceptible to Escherichia coli urinary tract infection. J Immunol 2007; 178:4717-4720.
44. Song J, Bishop BL, Li G, et al. TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder. Cell Host Microbe 2007; 1:287-298.
45. Song J, Abraham SN. TLR-mediated immune responses in the urinary tract. Curr Opin Microbiol 2008; 11:66-73.
46. Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 2008; 10:2568-2578.
47. Sivick KE, Schaller MA, Smith SN, Mobley HL. The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection. J Immunol 2010; 184:2065-2075.
48. Smith NJ, Varley CL, Eardley I, et al. Toll-like receptor responses of normal human urothelial cells to bacterial flagellin and lipopolysaccharide. J Urol 2011; 186:1084-1092.
49. Nielsen KL, Dynesen P, Larsen P, et al. Role of urinary cathelicidin LL-37 and human beta-defensin 1 in uncomplicated Escherichia coli urinary tract infections. Infect Immun 2014; 82:1572-1578.
50. Hiratsuka T, Nakazato M, Ihi T, et al. Structural analysis of human betadefensin-1 and its significance in urinary tract infection. Nephron 2000; 85:34-40.
51. Morrison G, Kilanowski F, Davidson D, Dorin J. Characterization of the mouse beta defensin 1, Defb1, mutant mouse model. Infect Immun 2002; 70:3053-3060.
52. Becknell B, Spencer JD, Carpenter AR, et al. Expression and antimicrobial function of beta-defensin 1 in the lower urinary tract. PLoS One 2013; 8:e77714.
53. Jaillon S, Moalli F, Ragnarsdottir B, et al. The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. Immunity 2014; 40:621-632.
54. Schiwon M, Weisheit C, Franken L, et al. Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium. Cell 2014; 156:456-468.
55. Hannan TJ, Roberts PL, Riehl TE, et al. Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. EBioMedicine 2014; 1:46-57.
56. Hood MI, Skaar EP. Nutritional immunity: transition metals at the pathogenhost interface. Nat Rev Microbiol 2012; 10:525-537.
57. Reigstad CS, Hultgren SJ, Gordon JI. Functional genomic studies of uropathogenic Escherichia coli and host urothelial cells when intracellular bacterial communities are assembled. J Biol Chem 2007; 282:21259-21267.
58. Paragas N, Kulkarni R, Werth M, et al. alpha-Intercalated cells defend the urinary system from bacterial infection. J Clin Invest 2014; 124:2963-2976.
59. Chan CY, St John AL, Abraham SN. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 2013; 38:349-359.
60. Shelburne CP, Nakano H, St John AL, et al. Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host Microbe 2009; 6:331-342.
61. Savchenko AS, Inoue A, Ohashi R, et al. Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol Int 2011; 61:290-297.
62. Navas-Nacher EL, Dardick F, Venegas MF, et al. Relatedness of Escherichia coli colonizing women longitudinally. Mol Urol 2001; 5:31-36.
63. Foxman B, Manning SD, Tallman P, et al. Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners. Am J Epidemiol 2002; 156:1133-1140.
64. Chen SL, Wu M, Henderson JP, et al. Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. Sci Transl Med 2013; 5:184ra60.
65. Yamamoto S, Tsukamoto T, Terai A, et al. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. J Urol 1997; 157:1127-1129.
66. Moreno E, Andreu A, Pigrau C, et al. Relationship between Escherichia coli strains causing acute cystitis in women and the fecal E. coli population of the host. J Clin Microbiol 2008; 46:2529-2534.
67. Elliott TS, Reed L, Slack RC, Bishop MC. Bacteriology and ultrastructure of the bladder in patients with urinary tract infections. J Infect 1985; 11:191-199.
68. Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A 2006; 103:14170-14175.
69. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 2001; 69:4572-4579.
70. Schilling JD, Lorenz RG, Hultgren SJ. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect Immun 2002; 70:7042-7049.
71. Blango MG, Ott EM, Erman A, et al. Forced resurgence and targeting of intracellular uropathogenic Escherichia coli reservoirs. PLoS One 2014; 9:e93327.
72. Duell BL, Carey AJ, Tan CK, et al. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J Immunol 2012; 188:781-792.
73. Mulvey MA, Lopez-Boado YS, Wilson CL, et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 1998; 282:1494-1497.
74. Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc Natl Acad Sci U S A 2000; 97:8829-8835.
75. Mysorekar IU, Isaacson-Schmid M, Walker JN, et al. Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection. Cell Host Microbe 2009; 5:463-475.
76. Hannan TJ, Mysorekar IU, Hung CS, et al. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 2010; 6:e1001042.
77. Langermann S, Palaszynski S, Barnhart M, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 1997; 276:607-611.
78. Thumbikat P, Waltenbaugh C, Schaeffer AJ, Klumpp DJ. Antigen-specific responses accelerate bacterial clearance in the bladder. J Immunol 2006; 176:3080-3086.
79. Hooton TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996; 335:468-474.
80. Scholes D, Hooton TM, Roberts PL, et al. Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000; 182:1177-1182.
81. Hawn TR, Scholes D, Li SS, et al. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS One 2009; 4:e5990.
82. Tabel Y, Berdeli A, Mir S. Association of TLR2 gene Arg753Gln polymorphism with urinary tract infection in children. Int J Immunogenet 2007; 34:399-405.
83. Karoly E, Fekete A, Banki NF, et al. Heat shock protein 72 (HSPA1B) gene polymorphism and Toll-like receptor (TLR) 4 mutation are associated with increased risk of urinary tract infection in children. Pediatr Res 2007; 61:371-374.
84. Schlager TA, LeGallo R, Innes D, et al. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol 2011; 186:2359-2364.
85. Hopkins WJ, Gendron-Fitzpatrick A, Balish E, Uehling DT. Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect Immun 1998; 66:2798-2802.
86. Mabeck CE. Treatment of uncomplicated urinary tract infection in nonpregnant women. Postgrad Med J 1972; 48:69-75.
87. Ferry SA, Holm SE, Stenlund H, et al. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004; 36:296-301.
88. Hansson S, Hanson E, Hjalmas K, et al. Follicular cystitis in girls with untreated asymptomatic or covert bacteriuria. J Urol 1990; 143:330-332.
89. Hannan TJ, Totsika M, Mansfield KJ, et al. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 2012; 36:616-648.
90. Henderson JP, Crowley JR, Pinkner JS, et al. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathog 2009; 5:e1000305.
91. Chaturvedi KS, Hung CS, Crowley JR, et al. The siderophore yersiniabactin binds copper to protect pathogens during infection. Nat Chem Biol 2012; 8:731-736.
92. Chaturvedi KS, Hung CS, Giblin DE, et al. Cupric yersiniabactin is a virulence-associated superoxide dismutase mimic. ACS Chem Biol 2014; 9:551-561.
93. Zhao Z, Fux B, Goodwin M, et al. Autophagosome-independent essential function for the autophagy protein Atg5 in cellular immunity to intracellular pathogens. Cell Host Microbe 2008; 4:458-469.
94. Wang C, Mendonsa GR, Symington JW, et al. Atg16L1 deficiency confers protection from uropathogenic Escherichia coli infection in vivo. Proc Natl Acad Sci U S A 2012; 109:11008-11013.
95. Wang C, Yuan X, Ma E, et al. NOD2 is dispensable for ATG16L1 deficiency-mediated resistance to urinary tract infection. Autophagy 2014; 10:331-338.
96. Hunstad DA, Justice SS, Hung CS, et al. Suppression of bladder epithelial cytokine responses by uropathogenic Escherichia coli. Infect Immun 2005; 73:3999-4006.
97. Loughman JA, Hunstad DA. Attenuation of human neutrophil migration and function by uropathogenic bacteria. Microbes Infect 2011; 13:555-565.
98. Lau ME, Loughman JA, Hunstad DA. YbcL of uropathogenic Escherichia coli suppresses transepithelial neutrophil migration. Infect Immun 2012; 80:4123-4132.
99. Lutay N, Ambite I, Gronberg Hernandez J, et al. Bacterial control of host gene expression through RNA polymerase II. J Clin Invest 2013; 123:2366-2379.
100. Duell BL, Carey AJ, Dando SJ, et al. Human bladder uroepithelial cells synergize with monocytes to promote IL-10 synthesis and other cytokine responses to uropathogenic Escherichia coli. PLoS One 2013; 8:e78013.
101. Pouwels SD, Heijink IH, ten Hacken NH, et al. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol 2014; 7:215-226.